Get started
ICON — Breakout from Rectangle with H Projection Targeting $700ICON (3D) — Technical Structure Analysis ICON has broken out from a prolonged horizontal rectangle pattern ($380–$540). The move activated a measured move structure with two H-sized waves. The first H was completed. The second H projects a move to the $700 area. Key points: -Confirmed breakout from range -First H = 153 pts, completed -Second H = 162 pts, targeting $700 -Price holding above breakout zone ($515–$541) ICON has moved out of accumulation and entered trend expansion. As long as the support holds, the scenario remains valid. The technical model targets the $700 area.
TASE:ICONLong
by TotoshkaTrades
Tel Aviv Stock Exchange: 3 Falling Peaks into a 3 Line StrikeBeyond just the implications of the war, the technical setup on the Tel Aviv Stock Exchange looks very Bearish as if it's ready to collapse to new lows, as it has confirmed 3 Falling Peaks and will confirm a 3 Line Strike on the Monthly Timeframe in just 14 hours. I expect that the exchange and all 15 of its Foreign and Domestic owners will be negatively affected in the process. Which mostly consist of Israeli Banks and Holdings Companies but also consist of Foreign banks such as UBS, BCS, HSBC, Citigroup, and Merrill Lynch International, which is owned by Bank of America, to name a few.
TASE:TASEShort
by RizeSenpai
ESLT - Elbit Systems - Interesting long-term perspective The weekly ElliotWave (EW) chart pattern on ESLT shows rather lucrative long-term potential. Besides that we may notice fine weekly cap-and-handle formation near all time highs 80780 area. Price shows relative strength to general TASE index (shown on the liner chart above) and I like how the volume and volatility subsides in the right handle area of the chart. If the price manages to break-out above 80780 pivot with rising volume, I would consider this constructive for any position/swing longs. In more granular view, with todays gap-up open with volume already approaching yesterdays highs, it is reasonable to consider opening initial position with tight staggered 3-5% stops, with an idea to add to position if price advances to and breaks-out from the long-term pivot point mentioned above Daily
TASE:ESLTLong
by artemfedorov
JBNK - Macro view is not certain, but break-out CaH on a Daily Weekly macro perspective has a nice diagonal pattern, that respects key support and resistance zones. Although it is hard to definitely state that primary wave 4 has found its bottom in Apr23 due to its relatively short timespan within the macro structure. But as I a low-risk trader I am not concerned with the overall wave pattern, but with what price and volume are doing in particular moment in time. That being sad, zooming in to the potential weekly handle zone, I really like how the pattern tightens and volatility subsides. 3 week tight closes in September also provides potential evidence for accumulation rather than distribution in place. Could be actionable above 1420, it the advance will be supported by volume and strength in overall market.
TASE:JBNKLong
by artemfedorov
NXSN/Next Vision - 2023 Rally may need to rest My ElliotWave (EW) analysis on NXSN shows that price has approached meaningful mid-term resistance zone at 2352-2627. If my technical thesis holds, price shall start digesting its 250% rally from Oct'22 bottom in near term, finishing its wave iii and starting corrective wave iv. Important and ideal EW support zone for this potential correction is 1760-1472, that coincides with advancing 200D moving average. From the trading perspective this is not exactly the area for any short selling attempt, because price has not broken even the short-term uptrend, staying above 8/21 EMAs and 50MA. One may even consider entertaining taking a long position on break out above 2400 zone with staggered 3-5% stops, although I would highly caution any attempt to trade it for the long-term move - only as a swing-trading approach (short-term), bearing in mind EW resistance zone mentioned above. The stock remains one of the strongest on TASE both technically and fundamentally. Impressive double and triple digits quarter Revenue and EBITDA growth. Any correction, followed by a base building process later this and early next year may present good investing/trading opportunities.
TASE:NXSNShort
by artemfedorov
TASE:KMDA KAMADA - is a developer of life saving therapeutics. A global specialty plasma-derived biopharmaceutical company with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. The Company’s strategy is focused on driving profitable growth from its current commercial products, its plasma-derived development pipeline and its manufacturing expertise, while evolving into a vertically integrated plasma-derived company. The Company’s two leading commercial products are GLASSIA® and KEDRRAB®. GLASSIA was the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the FDA. The Company markets GLASSIA in the U.S. through a strategic partnership with Takeda Pharmaceuticals Company Limited ("Takeda") and in other countries through local distributors. Pursuant to an agreement with Takeda, the Company will continue to produce GLASSIA for Takeda through 2021 and Takeda will initiate its own production of GLASSIA for the U.S. market in 2021, at which point Takeda will commence payment of royalties to the Company until 2040. KEDRAB is an FDA approved anti-rabies immune globulin (Human) for post-exposure prophylaxis treatment. KEDRAB is being marketed in the U.S. through a strategic partnership with Kedrion S.p.A. The Company has additional four plasma-derived products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia. The Company has two leading development programs; a plasmaderived hyperimmune immunoglobulin (IgG) product as a potential treatment for coronavirus disease (COVID-19) and an inhaled AAT for the treatment of AAT deficiency for which the Company is currently conducting the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. The Company leverages its expertise and presence in the Israeli pharmaceutical market to distribute in Israel more than 20 products that are manufactured by third parties and have recently added nine biosimilar products to its Israeli distribution portfolio, which, subject to EMA and the Israeli MOH approvals, are expected to be launched in Israel between the years 2022 and 2025. FIMI Opportunity Fund, the leading private equity investor in Israel, is the Company’s lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares. Letter from CEO (on Mar 15 2022): "Dear Shareholders, Colleagues and Business Partners: The recently completed 2021 year was a transformational period for Kamada in our path toward becoming a global leader in the plasma-derived specialty market. Following the completion of the planned manufacturing transition of Glassia® to Takeda, our recent acquisition of four FDA-approved commercial immunoglobulins and the establishment of Kamada Plasma, our U.S. based plasma collection company, we are embarking on a new and exciting chapter in the Company’s evolution. We are building on the strong foundation established over the years, entering 2022 as a "New Kamada" – a fully-integrated specialty plasma company with six FDA-approved products and strong commercial capabilities in the U.S. market, as well as a global commercial footprint in over 30 countries. Our business performed as expected in 2021 and we look ahead to 2022 for which our revenue guidance is between $125 million to $135 million, representing a 20% to 30% growth compared to 2021, with expected EBITDA margins of 12% to 15%, which would represent more than 2.5x the 2021 EBITDA. This strong guidance reflects the benefits stemmed from our new undertaken strategic direction, and the resume of revenue and profitability growth in 2022. Importantly, we further expect continued growth at a double-digit rate in the coming few years. The acquisition completed in November 2021, following a thorough search for the ideal assets for Kamada, was a critical strategic and synergistic step for the Company. The acquired products generated revenues exceeding $40 million in 2021, with over 50% gross margins, and we anticipate significantly growing the new portfolio’s revenues through proactive promotional activities in the U.S, where our newly established subsidiary, Kamada Inc., is responsible for the commercialization and direct sales of the products. We also intend to leverage our existing strong international distribution network to grow product revenue in new territories, primarily in Asia, Latin America and the Middle East. I am pleased to report that these promotional and sales activities have already commenced. Of the four acquired products, the largest is Cytogam®, indicated for the prophylaxis of cytomegalovirus disease associated with solid organs transplantation. This proprietary and unique product is the only FDA-approved IgG product for its indication. The transition of Cytogam manufacturing to our facility is already well underway, and we expect to receive FDA approval for its production at our Israeli facility by early 2023. Moreover, based on the Cytogam manufacturing transfer, expected growth of KedRAB®, our FDA-approved anti-Rabies hyperimmune product, and planned manufacturing transition of the other acquired products over the next few years, we anticipate improving the gross margins of our proprietary products by effectively utilizing our plant capacity. Another major strategic step taken is the acquisition of a plasma collection facility in Texas, in early 2021, which primarily specializes in the collection of hyper-immune plasma used for Anti-D immunoglobulin, a product manufactured by Kamada and distributed in international markets. This acquisition represented Kamada’s entry into the U.S. plasma collection market and supported our strategic goal of becoming a fully integrated specialty plasma company. We are already actively engaged in the expansion of the hyperimmune plasma collection capacity at this center and are simultaneously advancing our plan to open additional centers in the U.S. to further enhance our supply of specialty and regular plasma. KedRAB, marketed in the U.S by Kedrion, continues to gain market share in the $150 million U.S. market. During 2021 the FDA approved a label expansion for the product which differentiates KedRAB as the first and only human rabies immunoglobulin (HRIG) available in the U.S. to be clinically studied in children and confirming the safety and effectiveness of its use in pediatric population. We anticipate sales of the product to grow significantly during the next few years."
TASE:KMDA
by sequentialvision